GSK seeks EU marketing approval for lupus drug
Says to seek U.S. FDA approval by end June
Wednesday, June 9, 2010
GlaxoSmithKline Plc has sought European regulators' marketing approval for its experimental lupus drug Benlysta, being developed along with Human Genome Sciences Inc, the companies said.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms